Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 625-630

  Shigematsu, Yoshiki ^a   Hanagiri, Takeshi ^a   Shiota, Hironobu ^a   Kuroda, Koji ^a   Baba, Tetsuro ^a   Ichiki, Yoshinobu ^a   Yasuda, Manabu ^a   Uramoto, Hidetaka ^a   Takenoyama, Mitsuhiro ^a   Yasumoto, Kosei ^a   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Cytotoxic t lymphocytes; Immune escape mechanism; Non small cell lung cancer; Regional lymph node lymphocytes; Regulatory T cells

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; AUTOLOGOUS MIXED LYMPHOCYTE REACTION; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURGERY; CD4+ CD25+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE CELL; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84864708909     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.815     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Sangha R and Butts C: L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 13: 4652-4654, 2007.
3. Vansteenkiste J, Zielinski M, Linder A, et al: Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol (Suppl 25): 398s, 2007.
4. van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
5. Ichiki Y, Takenoyama M, Mizukami M, et al: Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 172: 4844-4850, 2004.
6. Takenoyama M, Baurain JF, Yasuda M, et al: A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytyic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 118: 1992-1997, 2006.
7. Pages F, Berger A, Camus M, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666, 2005.
8. Zhang L, Conejo-Garcia JR, Katsaros D, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003.
9. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
10. Levings MK, Sangregorio R and Roncarolo MG: Human cd25(+)cd4(+) t regulatory cells suppress naïve and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193: 1295-1302, 2001.
11. Shevach EM: Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193: 41-46, 2001.
12. Jonuleit H, Schmitt E, Schuler G, Knop J and Enk AH: Induction of interleukin 10-producing, non proliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192: 1213-1222, 2000.
13. Read S and Powrie F: CD4(+) regulatory T cells. Curr Opin Immunol 13: 644-649, 2001.
14. Gibbs AR and Thunnissen FB: Histological typing of lung and pleural tumours: third edition. J Clin Pathol 54: 498-499, 2001.
15. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111: 1710-1717, 1997.
16. Sugaya M, Takenoyama M, Osaki T, et al: Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 122: 282-288, 2002.
17. Takenoyama M, Yoshino I, Eifuku R, et al: Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res 92: 309-315, 2001.
18. Fukuyama T, Ichiki Y, Yamada S, et al: Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci 98: 1048-1054, 2007.
19. Sakaguchi S, Ono M, Setoguchi R, et al: Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8-27, 2006.
20. Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336, 2003.
21. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E and Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612, 2003.
22. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464, 2005.
23. Woo EY, Chu CS, Goletz TJ, et al: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772, 2001.
24. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
25. Bates GJ, Fox SB, Han C, et al: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380, 2006.
26. Ghiringhelli F, Menard C, Terme M, et al: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-h-dependent manner. J Exp Med 202: 1075-1085, 2005.
27. Petersen RP, Campa MJ, Sperlazza J, et al: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107: 2866-2872, 2006.
28. Marie JC, Letterio JJ, Gavin M and Rudensky AY: TGF-beta 1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201: 1061-1067, 2005.
29. Wieczorek G, Asemissen A, Model F, et al: Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 69: 599-608, 2009.
30. Walunas TL, Bakker CY and Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183: 2541-2550, 1996.
31. Krummel MF and Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182: 459-465, 1995.
32. Read S, Malmstrom V and Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192: 295-302, 2000.
33. Salomon B, Lenschow DJ, Rhee L, et al: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440, 2000.
34. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD and Bluestone JA: CTLA-4: A negative regulator of autoimmune disease. J Exp Med 184: 783-788, 1996.
35. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A and Allison JP: CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 162: 5813-5820, 1999.
36. Leach DR, Krummel MF and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736, 1996.
37. van Elsas A, Hurwitz AA and Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355-366, 1999.
38. van Elsas A, Sutmuller RP, Hurwitz AA, et al: Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194: 481-489, 2001.
39. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100: 4712-4717, 2003.
40. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377, 2003.
41. Hodi FS, Butler M, Oble DA, et al: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105: 3005-3010, 2008.
42. Korman AJ, Peggs KS and Allison JP: Checkpoint blockade in cancer immunotherapy. Adv Immunol 90: 297-339, 2006.
43. Ribas A, Hanson DC, Noe DA, et al: Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12: 873-883, 2007.
44. Yamaguchi T, Hirota K, Nagahama K, et al: Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27: 145-159, 2007.